The purpose of this study is to assess safety, tolerability, preliminary efficacy, and PK of TAK-671 in participants with COVID-19.
The drug being tested in this study is called TAK-671. The study will evaluate the safety,
tolerability and PK of TAK-671 in participants admitted to the hospital with a confirmed
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) positive test.
The study will enroll approximately 40 participants. Each cohort will have 20 participants.
Participants will be randomly assigned (by chance, like flipping a coin) in a 3:1 ratio to
receive TAK-671 or placebo in each cohort, which will remain undisclosed to the participant
during the study (unless there is an urgent medical need):
- Cohort 1: TAK-671 Low Dose
- Cohort 2: TAK-671 High Dose
Enrollment in Cohort 2 will only begin once all 20 participants in Cohort 1 have reached Day
7 post dose and have received positive review from the internal review committee (IRC) and
approval to continue enrollment. All participants will receive the standard of care along
with the study treatment.
This multi-center trial will be conducted in the United States. The overall time to
participate in this study is approximately 3 months. All participants will be followed up 28
days after the infusion.
Drug: TAK-671
TAK-671 intravenous infusion.
Other Name: SB26
Drug: TAK-671 Placebo
TAK-671 placebo-matching intravenous infusion.
Other Name: SB26/TAK-671 matching-placebo
Inclusion Criteria:
1. Has laboratory-confirmed SARS-CoV-2 infection as determined via polymerase chain
reaction or an accepted molecular assay of any specimen, example, respiratory, blood,
urine, stool, other body fluid.
2. It has been less than 72 hours since time of the participant's hospital admission, or,
if hospital acquired COVID-19 is confirmed, less than 72 hours after confirmation of
positive SARS-CoV-2 test or the onset of respiratory symptoms, whichever is first.
3. Has peripheral capillary SpO2 less than or equal to 93% on room air.
4. Weighs greater than or equal to (>=) 50 kilogram (kg) and has a body mass index (BMI)
18 to 35 kilogram per square meter (kg/m^2), inclusive.
5. Female participants are post-menopausal or surgically sterile.
Exclusion Criteria:
1. Has received TAK-671 or ulinastatin (UTI) in a previous clinical study or as a
therapeutic agent.
2. Has received a human blood product (other than a transfusion needed for trauma
treatment) or has been treated with a monoclonal antibody or Fc-fusion biologic within
5 years of the screening visit.
3. Has evidence of multiorgan failure, based on a SOFA score greater than 12.
4. Is on invasive mechanical ventilation.
5. Requires vasopressor support. (However, use of fluid support is not exclusionary.)
6. Has known or suspected venous thromboembolism.
7. Any female participant who is of child-bearing potential or is breastfeeding.
8. Has active tuberculosis or a clinical suspicion of latent tuberculosis.
9. Has fulminant hepatic or renal failure.
10. Has congestive heart failure of New York Heart Association Grade III or IV, pulmonary
embolism, or any other serious cardiac condition (example, pericardial effusion or
restrictive cardiomyopathy).
11. Participant's progression to death is imminent and inevitable within the next 24
hours, regardless of cause and irrespective of the provision of treatments, in the
opinion of the investigator.
12. Has a life expectancy of less than 6 months due to reasons other than COVID-19 in the
opinion of the investigator.
13. Has a do-not-resuscitate or do-not-intubate (DNR/DNI) order.
Medical Director, Study Director
Takeda